InvestorsHub Logo

mick

08/08/20 10:45 AM

#53 RE: manysevens #52

$KIN outstanding chart review.breakout saucer review, very bullish !!!!!

mick

08/08/20 10:46 AM

#54 RE: manysevens #52

$KIN outstanding Quarterly Report (10-q) Edgar (US

mick

08/08/20 10:56 AM

#56 RE: manysevens #52

$KIN pay attention to dis partnering wit $VXRT manufacture of Vaxart’s oral vaccine candidate for COVID-19.

re;
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,

today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.

“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.

We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,

Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”

Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.

There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.

KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.

“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,

Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”

KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.

mick

08/20/20 10:17 AM

#84 RE: manysevens #52

$KIN I LIKE YOUR BREAKOUT ANYTIME[SAUCER FORMATION]

mick

08/20/20 10:23 AM

#85 RE: manysevens #52

$KIN DIS CHART [$KIN *V* BREAKOUT POSSIBLE REVERSE H&S PATTERN]was $11

[-chart]finviz.com/chart.ashx?t=KIN&ty=c&ta=1&p=d&s=l[/chart]

mick

08/20/20 7:50 PM

#98 RE: manysevens #52

$KIN making breakout move my friend , why is everybody picking on $KIN ?????

mick

08/20/20 7:54 PM

#99 RE: manysevens #52

$KIN huge earnings report[heavy]Kindred Biosciences Q2 EPS $0.60 Up From $(0.37) YoY,

Sales $39.57M May Not Compare To $10.54M Estimate

4:26 pm ET August 5, 2020 (Benzinga) Print


Kindred Biosciences (NASDAQ:KIN) reported quarterly earnings of $0.60 per share.

This is a 262.16 percent increase over losses of $(0.37) per share
from the same period last year.

The company reported quarterly sales of $39.57 million which beat
the analyst consensus estimate of $10.54 million by 275.40 percent.

This is a 3.10K percent increase over
sales of $1.24 million the same period last year.

© 2020 http://www.Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

mick

08/20/20 7:54 PM

#100 RE: manysevens #52

$KIN huge earnings report[heavy]Kindred Biosciences Q2 EPS $0.60 Up From $(0.37) YoY,

Sales $39.57M May Not Compare To $10.54M Estimate

4:26 pm ET August 5, 2020 (Benzinga) Print


Kindred Biosciences (NASDAQ:KIN) reported quarterly earnings of $0.60 per share.

This is a 262.16 percent increase over losses of $(0.37) per share
from the same period last year.

The company reported quarterly sales of $39.57 million which beat
the analyst consensus estimate of $10.54 million by 275.40 percent.

This is a 3.10K percent increase over
sales of $1.24 million the same period last year.

© 2020 http://www.Benzinga.com. Benzinga does not provide investment advice. All rights reserved.